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Ovarian cryopreservation is a promising technique to preserve fertility in women with Hodgkin lymphoma (HL) treated with
chemotherapy. Thus, the aim of this study was to examine harvested ovarian tissue for subclinical involvement by HL by morphology/
immunohistochemistry, and to define patient and treatment factors predictive of oocyte yield. This was a retrospective analysis of 26
ovarian tissue samples harvested for cryopreservation from women with HL. Histology, immunohistochemistry and follicle density
(numbermm
 3) was examined. Disease status and preharvest chemotherapy details were obtained on 24 patients. The median age
was 22 years (range 13–29). Seven of 24 patients had infradiaphragmatic disease at time of harvest. Nine of 20 patients had received
chemotherapy preharvest (ABVD (Adriamycin
s, Bleomycin, Vinblastine and Dacarbazine)¼7, other regimens¼2). The seven
receiving ABVD showed no difference in follicle density compared to patients not receiving treatment (n¼14); (median¼1555 vs
1620mm
3 P¼0.97). Follicle density measurement showed no correlation with patient age (R
2¼0.0001, P¼0.99). There was no
evidence of HL involvement in the 26 samples examined (95% CI¼0–11%). In conclusion, subclinical involvement of HL has not
been identified in ovarian tissue, even when patients have infradiaphragmatic disease. Furthermore, the quality of tissue harvested
does not appear to be adversely affected by patient’s age or prior ABVD chemotherapy.
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As Hodgkin lymphoma (HL) is a common malignancy in young
people (Blumenfeld et al, 2002), fertility preservation is an
important issue to address when counselling patients prior to
chemotherapy. With current regimens of chemotherapy and
radiotherapy a large proportion of patients will be cured of their
illness, but with the risk of long-term toxicity, particularly with
recently developed intensive chemotherapy programmes such as
escalated-dose BEACOPP (Bleomycin, Etoposide, Adriamycin
s,
Cyclophosphamide, Oncovin
s, Procarbazine, Prednisolone)
(Diehl et al, 2003).
A major concern for female patients is the risk of long-term
infertility and premature ovarian failure. Depending on the
chemotherapy regimen used this risk can range from very low
(0–10%) with ABVD (Adriamycin
s, Bleomycin, Vinblastine and
Dacarbazine) (Seymour, 2001) to high (B50%) with BEACOPP
(Behringer et al, 2004) and very high for those who require bone
marrow transplantation (Mertens et al, 1998; Watson et al, 1999;
Grigg, 2004).
Unlike sperm cryopreservation, oocyte preservation is invasive
and burdensome for patients and has so far had limited
applicability in humans. Embryo cryopreservation has a pregnancy
rate of 15–25%, but as considerable time is required to obtain
mature follicles chemotherapy administration may be delayed
with potential detrimental effect on patient outcome. Moreover,
this option requires donor sperm, often not available to women
without a stable partner, which will often be the case among
adolescents and young adult women (Wood et al, 1997).
Ovarian cryopreservation is a promising strategy for preserving
fertility in these patients. Harvesting of ovarian tissue via
laparoscopic surgery can be performed at any time during the
menstrual cycle. Furthermore, the removal and appropriate
cryopreservation of a small area of ovary containing an abundance
of primordial follicles has more theoretical potential for future
fertility than cryopreserved oocytes (Gook et al, 1999, 2003). This
tissue can then be reimplanted either orthotopically (Radford et al, Received 30 November 2005; revised 16 February 2006; accepted 16
February 2006; published online 28 March 2006
*Correspondence: Dr JF Seymour;
E-mail: John.Seymour@petermac.org
British Journal of Cancer (2006) 94, 1007–1010
& 2006 Cancer Research UK All rights reserved 0007– 0920/06 $30.00
www.bjcancer.com
C
l
i
n
i
c
a
l
S
t
u
d
i
e
s2001; Meirow et al, 2005), or heterotopically (Donnez et al, 2004;
Oktay et al, 2004; Wolner-Hanssen et al, 2005), with the
demonstrated capacity to restore both endocrine function and
fertility (Donnez et al, 2004; Meirow et al, 2005).
The data on the success of this procedure is largely limited to
animal studies and case reports. It has been demonstrated that
murine recipients of cryopreserved ovaries have had successful
pregnancies (Gunasena et al, 1997; Shaw et al, 2000). Autotrans-
plantation using fresh ovarian tissue has been successful in
reinstating monkeys’ ovarian cycles and producing oocytes
resulting in pregnancy with subsequent live birth (Lee et al, 2004).
In humans, there has been a report of a temporary restoration of
endocrine function after cryopreserved ovarian tissue was auto-
transplanted back into a patient with HL (Radford et al, 2001). In
addition, there have been two reports of a successful pregnancy
and live birth, which resulted from the reimplantation of frozen
ovarian tissue into patients with HL and non-Hodgkin’s lymphoma
(NHL) (Donnez et al, 2004; Meirow et al, 2005).
One of the potential concerns with this procedure is the risk of
disease reimplantation. Lymphoma involving the ovary is indeed
rare. However, there has been at least one case report of clinically
manifest HL involving the ovary (Khan et al, 1986) and a report of
HL resulting in omental caking (Jacobs et al, 1996). Thus, there is
the potential for occult ovarian involvement at the time of tissue
harvesting. There are only two reports of histological assessment of
cryopreserved ovarian tissue in patients with HL and neither of
these found any evidence of HL involvement of the harvested
tissue by light microscopy (Meirow et al, 1998; Kim et al, 2001).
Kim et al (2001) xenotransplanted ovarian tissue from women with
HL into immunodeficient mice and found no evidence of disease
transmission, although the capacity of primary HL cells to grow in
such a xenograft model is unknown. Nevertheless, a murine study
has shown the capacity of reimplanted syngeneic ovarian tissue to
transmit lymphoma in six out of seven cases, however, this study
was performed using a high grade NHL (Shaw et al, 1996).
Another difficulty is identifying patients where the harvested
tissue will contain adequate numbers of follicles. A single case
report suggested that tissue collected after previous chemotherapy
may contain marginal numbers of follicles with subsequent
transient functional capacity after reimplantation (Radford et al,
2001). There have been no prior studies exploring factors
associated with the adequacy of follicle numbers in harvested
ovarian tissue.
The aim of this study was to examine the ovarian tissue
harvested from a cohort of young women with HL for subclinical
involvement with lymphoma using sensitive and specific immuno-
histochemistry. We also aimed to define patient and treatment
factors that may play a role in the quality of the tissue harvested.
MATERIALS AND METHODS
Patients
This was a retrospective analysis of ovarian tissue samples
obtained from 26 women with HL aged between 13 and 29 years
who had undergone ovarian tissue harvest at laparoscopy between
December 1995 and August 2005. All patients were referred to
Reproductive Services/Melbourne IVF, Royal Women’s Hospital
for fertility preservation by their treating oncologist. The point in
treatment when this tissue was obtained was left to the discretion
of the treating physician and the patient. Consent was obtained for
both the laparoscopic removal and storage of ovarian tissue and
histological examination.
Details of the patients’ disease and treatment were obtained
from the treating physicians’ medical records via a questionnaire
completed by the treating physician. Preharvest patient and
treatment characteristics were subsequently correlated with the
ovarian histology and follicle density. Data regarding premature
ovarian failure in the cohort following HL treatment was not
collated.
Ovarian tissue cryopreservation
A wedge section of ovary (surface area 1–6cm
2) was removed in
all but two patients in whom a whole ovary was removed. A small
area was fixed immediately in 10% formalin for histological and
immunohistochemical analysis. The remaining tissue was trimmed
to approximately 1mm thick, removing all medulla and subse-
quently cut into small slices (B2 4mm). The cryopreservation
procedure has been previously described in detail (Gook et al,
1999). Briefly, the slices were soaked in cryoprotectant (1.5moll
 1
propanediol and 0.1moll
 1 sucrose in phosphate buffered saline)
for 90min, followed by cooling in a control rate freezing machine
to  1501C and stored in liquid nitrogen vapour.
Follicle density and immunohistochemistry
Fixed tissue was processed and embedded in paraffin wax.
Histological sections, stained with haematoxylin and eosin, were
screened for ovarian follicles and the presence of the distinctive
malignant Reed–Sternberg (RS) cells characteristic of HL. A
minimum of 10 sections selected randomly throughout the fixed
piece of ovarian tissue were examined to determine follicle density
(number per cubic mm).
Additional sections were examined for the presence of
malignant cells expressing the surface markers CD15 and CD30
characteristic of HL. These two markers were chosen as RS cells
are positive for CD30 in up to 100% of cases (Stein et al, 1985) and
the incidence of CD15 positivity is very high at 75–85% (Jaffe et al,
2001). Thus, a minimum of three random sections per patient of
both ovarian cortex and medulla were examined histologically for
involvement with HL by a single independent expert pathologist.
Following heat antigen retrieval for 2min in 10mmoll
 1 citrate
buffer pH 6.0 at 1251C, sections were incubated with primary
antibody (CD15 – 1 in 50 dilution of clone MMA, Becton
Dickinson, Franklin Lakes, New Jersey, USA; CD30 – 1 in 400
dilution of clone Ber-H2, Dakocytomation) for 30min at room
temperature. Sections were washed and incubated with a second
antibody conjugated to a horseradish peroxidase DAB detection
system (Mouse Envision, Dakocytomation).
All statistical analyses were performed using Minitab software.
RESULTS
Data regarding patient’s disease status were available for 24 of the
26 patients and are outlined in Table 1.
Nine patients had received chemotherapy prior to harvest with
seven patients receiving ABVD, one received Stanford V (Horning
et al, 2002) and one ChlVPP (chlorambucil, vinblastine, procarba-
zine, prednisolone), etoposide/vincristine/epirubicin. The median
number of ABVD cycles received prior to harvest was 6 (range
2–6). The median time between the final cycle of ABVD chemo-
therapy and ovarian harvest was 2 months (range 2–24 months).
At diagnosis of HL nine patients had stage III or stage IV disease
and at the time of harvest seven patients had disease below the
diaphragm. Of these seven patients five had intra-abdominal
disease, one had bony disease in the femur and in one patient the
exact site(s) of infradiaphragmatic disease at the time of harvest
were not recorded.
There was no evidence of HL involvement by morphology or
immunohistochemistry in any of the 26 samples examined (95%
CI for ‘true’ rate of involvement¼0–11%). No inflammatory
infiltrate or any other atypical findings were noted in the samples
examined.
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sThe range of follicle densities was 45–4512folliclesmm
 3 for
the 26 patients. The seven patients who had received ABVD
chemotherapy preharvest showed no statistical difference in
follicle density compared to patients not receiving treatment
(n¼14) (median number of follicles for those receiving ABVD
was 1555mm
3 (range 45–4512mm
3) vs 1620mm
3, (range 459–
2840mm
3) for those not receiving prior treatment, P¼0.97).
Follicle density measurement for the entire cohort and for the 14
untreated patients showed no correlation with patient age
(R
2¼0.0001, P¼0.99 and R
2¼0.011, P¼0.93, respectively).
DISCUSSION
With technology continually improving for cryopreservation and
now with successful pregnancies from this technique, the safety
and timing of ovarian harvesting are important issues to address.
We did not identify any histological evidence of lymphomatous
involvement in 26 patients with HL undergoing ovarian harvesting
despite some patients having definite intra-abdominal disease
at the time of ovarian collection. While we cannot exclude the
possibility of disease involvement in all cases, our data suggest the
frequency is likely to be very low. Possible risk factors for
involvement may be predicted to be intra-abdominal disease and
the presence of B symptoms at the time of collection as these
features imply more aggressive disease behaviour. Studies of ‘high
risk’ patients are needed to better define the risk of ovarian
involvement in these specific settings.
One of the main hurdles to overcome with ovarian cryopre-
servation is the loss of primordial follicles due to ischaemia prior
to revascularisation. Thus, optimal follicle yield is of paramount
importance. Although follicle density was determined from a single
biopsy and distribution varies throughout the ovary, the follicle
densities for the HL patients are similar to those observed for a
group of young women with other types of cancer (Gook et al,
2005). Whether a single biopsy of an ovary is adequate to exclude
HL involvement of the entire ovary is uncertain and one should
consider random examination of several slices within the biopsy
specimen prior to autotransplantation of the remaining tissue.
In this study, we used immunohistochemistry in addition to
morphology to identify RS cells, as it has been shown to be very
sensitive (Stein et al, 1985; Jaffe et al, 2001). One must note that RS
cells are very fragile and are easily damaged by some cell
manipulation procedures (Irsch et al, 1998). Thus, although there
is no data available, it is possible that the cryopreservation process
may selectively damage RS cells, thus making examination of
poststorage tissue less sensitive. However, our histological analysis
was performed on tissue prior to the cryopreservation process.
Furthermore, RS cells are generally associated with a rich
inflammatory cell background and this was not evident in the
ovarian sections examined. One additional point to note is that a
number of tumours have recently been shown to be derived from a
small population of ‘cancer stem cells’ (Zhang and Rosen, 2006). It
is currently unknown whether such a stem-cell pool for RS cells
exists, but if this were the case, it is unclear whether the
immunohistochemical screen used here would detect these rare
cells putatively able to transfer the tumour.
This paper also addresses what factors may influence the quality
of the ovarian tissue harvested. Not surprisingly given the young
age of patients with HL analysed in our series (maximum 29 years),
age did not adversely affect the quality of the tissue harvested.
Furthermore, we also found no difference in the quality of tissue
harvested between those patients who had prior ABVD chemo-
therapy and those who had no prior treatment. This is relevant
given that a large proportion of patients are cured of their disease
with ABVD chemotherapy with the retention of their fertility.
Thus, we do not recommend routine collection prior to ABVD
chemotherapy, but rather at relapse prior to salvage therapy or at
primary diagnosis if intensified therapy (such as escalated
BEACOPP) is planned. This is in contrast to the Edinburgh
criteria recently published (Wallace et al, 2005), which recommend
that only patients who have not received chemotherapy be selected
as candidates for ovarian cryopreservation. Given the considerable
costs involved and the need for invasive surgery this recommen-
dation may need to be modified. We do note, however, that in our
study the median number of cycles of ABVD chemotherapy
administered was six and it is possible that more cycles of
chemotherapy could be associated with reduced follicle density on
harvest. Furthermore, even though ABVD is generally viewed as
having a very low risk for sterility, older patients receiving
numerous cycles of ABVD are more likely to suffer premature
infertility and thus may benefit from ovarian harvest prior to
treatment. It is unsure whether prior chemotherapy will influence
the ability of the graft to revascularise once it has been
transplanted back into the host or whether many of the follicles
are atretic – a characteristic that is difficult to determine from light
microscopy alone – (Familiari et al, 1993) and further studies are
required to explore these issues. None of our patients have had
their ovarian tissue reimplanted thus the in vivo characteristics of
the harvested tissue is not known.
In conclusion, ovarian harvesting appears to be a feasible
consideration in young female patients with HL even in those with
intra-abdominal involvement and that prior chemotherapy with
nonsterilising regimes such as ABVD does not adversely influence
the follicle yield.
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Table 1 Patient characteristics
Age Years
Median (year) 22; range (13–29)
Histological subtype n (%)
Nodular sclerosing 23 (96)
Mixed cellularity 1 (4)
Stage at diagnosis n (%)
I/II 15 (63)
III/IV 9 (37)
B symptoms at diagnosis n (%)
Yes 9 (37)
No 15 (63)
Immunophenotype n
CD30+ 6
CD 15+ 5
Not performed 16
Disease sites at time of harvest n (%)
Disease below diaphragm 7 (29)
Disease above diaphragm only 16 (67)
Unknown 1 (4)
Prior treatment n (%)
Nil 14 (58)
ABVD 7 (29)
Other chemotherapy 2 (8)
Radiotherapy to abdomen 2 (8)
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